BACKGROUND: Chronic gastrointestinal dysmotility greatly impacts the quality of life. Treatment options are limited and generally symptomatic. Neural autoimmunity is an under-recognized etiology. We evaluated immunotherapy as an aid to diagnosing autoimmune gastrointestinal dysmotility (AGID). METHODS: Twenty-three subjects evaluated at the Mayo Clinic for suspected AGID (August 2006-February 2014) fulfilled the following criteria: (1) prominent symptoms of gastrointestinal dysmotility with abnormalities on scintigraphy-manometry; (2) serological evidence or personal/family history of autoimmune disease; (3) treated by immunotherapy on a trial basis, 6-12 weeks (intravenous immune globulin, 16; or methylprednisolone, 5; or both, 2). Response was defined subjectively (symptomatic improvement) and objectively (gastrointestinal scintigraphy/manometry studies). KEY RESULTS: Symptoms at presentation: constipation, 18/23; nausea or vomiting, 18/23; weight loss, 17/23; bloating, 13/23; and early satiety, 4/23. Thirteen patients had personal/family history of autoimmunity. Sixteen had neural autoantibodies and 19 had extra-intestinal autonomic testing abnormalities. Cancer was detected in three patients. Preimmunotherapy scintigraphy revealed slowed transit (19/21 evaluated; gastric, 11; small bowel, 12; colonic, 11); manometry studies were abnormal in 7/8. Postimmunotherapy, 17 (74%) had improvement (both symptomatic and scintigraphic, five; symptomatic alone, eight; scintigraphic alone, four). Nine responders re-evaluated had scintigraphic evidence of improvement. The majority of responders who were re-evaluated had improvement in autonomic testing (six of seven) or manometry (two of two). CONCLUSIONS & INFERENCES: This proof of principle study illustrates the importance of considering an autoimmune basis for idiopathic gastrointestinal dysmotility and supports the utility of a diagnostic trial of immunotherapy.
BACKGROUND:Chronic gastrointestinal dysmotility greatly impacts the quality of life. Treatment options are limited and generally symptomatic. Neural autoimmunity is an under-recognized etiology. We evaluated immunotherapy as an aid to diagnosing autoimmune gastrointestinal dysmotility (AGID). METHODS: Twenty-three subjects evaluated at the Mayo Clinic for suspected AGID (August 2006-February 2014) fulfilled the following criteria: (1) prominent symptoms of gastrointestinal dysmotility with abnormalities on scintigraphy-manometry; (2) serological evidence or personal/family history of autoimmune disease; (3) treated by immunotherapy on a trial basis, 6-12 weeks (intravenous immune globulin, 16; or methylprednisolone, 5; or both, 2). Response was defined subjectively (symptomatic improvement) and objectively (gastrointestinal scintigraphy/manometry studies). KEY RESULTS: Symptoms at presentation: constipation, 18/23; nausea or vomiting, 18/23; weight loss, 17/23; bloating, 13/23; and early satiety, 4/23. Thirteen patients had personal/family history of autoimmunity. Sixteen had neural autoantibodies and 19 had extra-intestinal autonomic testing abnormalities. Cancer was detected in three patients. Preimmunotherapy scintigraphy revealed slowed transit (19/21 evaluated; gastric, 11; small bowel, 12; colonic, 11); manometry studies were abnormal in 7/8. Postimmunotherapy, 17 (74%) had improvement (both symptomatic and scintigraphic, five; symptomatic alone, eight; scintigraphic alone, four). Nine responders re-evaluated had scintigraphic evidence of improvement. The majority of responders who were re-evaluated had improvement in autonomic testing (six of seven) or manometry (two of two). CONCLUSIONS & INFERENCES: This proof of principle study illustrates the importance of considering an autoimmune basis for idiopathic gastrointestinal dysmotility and supports the utility of a diagnostic trial of immunotherapy.
Authors: Valeria Iodice; Axel Lipp; J Eric Ahlskog; Paola Sandroni; Robert D Fealey; Joseph E Parisi; Joseph Y Matsumoto; Eduardo E Benarroch; Kurt Kimpinski; Wolfgang Singer; Tonette L Gehrking; Jade A Gehrking; David M Sletten; Ann M Schmeichel; James H Bower; Sid Gilman; Juan Figueroa; Phillip A Low Journal: J Neurol Neurosurg Psychiatry Date: 2012-01-06 Impact factor: 10.154
Authors: J W Meeusen; K E Haselkorn; J P Fryer; T J Kryzer; S J Gibbons; Y Xiao; V A Lennon Journal: Neurogastroenterol Motil Date: 2012-10-17 Impact factor: 3.598
Authors: Darrell S Pardi; Steven M Miller; Daniel L Miller; Lawrence J Burgart; Joseph H Szurszewski; Vanda A Lennon; Gianrico Farrugia Journal: Am J Gastroenterol Date: 2002-07 Impact factor: 10.864
Authors: Jeremy K Cutsforth-Gregory; Andrew McKeon; Elizabeth A Coon; David M Sletten; Mariana Suarez; Paola Sandroni; Wolfgang Singer; Eduardo E Benarroch; Robert D Fealey; Phillip A Low Journal: Mayo Clin Proc Date: 2018-08-28 Impact factor: 7.616
Authors: Henry P Parkman; Mark L Van Natta; Ashima Makol; Madhusudan Grover; Richard W McCallum; Zubair Malik; Kenneth L Koch; Irene Sarosiek; Braden Kuo; Robert J Shulman; Gianrico Farrugia; Laura Miriel; James Tonascia; Frank Hamilton; Pankaj J Pasricha; Thomas L Abell Journal: Neurogastroenterol Motil Date: 2021-10-01 Impact factor: 3.960
Authors: Matthew Heckroth; Robert T Luckett; Chris Moser; Dipendra Parajuli; Thomas L Abell Journal: J Clin Gastroenterol Date: 2021-04-01 Impact factor: 3.174